Indeed, PI3KCA mutations have been found in approximately 3.5% of EGFR mutation-positive patients (91) and appear to be an indicator of resistance and poor survival for NSCLC patients treated with EGFR-TKIs (92). Here, EGFR is linked to non-small cell lung carcinoma.